<<Previous
|
Next>>
|
|
Response
Page 1 of 1
(749 of 749 records)
|
|
# |
DataId |
Indicator |
Value |
Precision |
DHS_CountryCode |
CountryName |
SurveyYear |
SurveyId |
IndicatorId |
IndicatorOrder |
IndicatorType |
CharacteristicId |
CharacteristicOrder |
CharacteristicCategory |
CharacteristicLabel |
ByVariableId |
ByVariableLabel |
IsTotal |
IsPreferred |
SDRID |
RegionId |
SurveyYearLabel |
SurveyType |
DenominatorWeighted |
DenominatorUnweighted |
CILow |
CIHigh |
LevelRank |
1 |
10558
|
SP/Fansidar use during pregnancy
|
4.7
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
2 |
10559
|
SP/Fansidar 2+ doses during pregnancy
|
2.8
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
3 |
10557
|
SP/Fansidar 3+ doses during pregnancy
|
1.5
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
4 |
10560
|
SP/Fansidar use during antenatal visit
|
4.1
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
5 |
10561
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
2.4
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
6 |
10562
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
1.4
|
1
|
AO
|
Angola
|
2006
|
AO2006MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006-07
|
MIS
|
1015
|
1095
|
|
|
|
7 |
197478
|
SP/Fansidar use during pregnancy
|
30.1
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
8 |
197479
|
SP/Fansidar 2+ doses during pregnancy
|
18.6
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
9 |
197486
|
SP/Fansidar 3+ doses during pregnancy
|
8.4
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
10 |
197483
|
SP/Fansidar use during antenatal visit
|
28.3
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
11 |
197484
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
17.5
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
12 |
197485
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
7.9
|
1
|
AO
|
Angola
|
2011
|
AO2011MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
MIS
|
3096
|
3120
|
|
|
|
13 |
436545
|
SP/Fansidar use during pregnancy
|
55.9
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
14 |
436547
|
SP/Fansidar 2+ doses during pregnancy
|
38.4
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
15 |
436546
|
SP/Fansidar 3+ doses during pregnancy
|
20
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
16 |
436571
|
SP/Fansidar use during antenatal visit
|
53.9
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
17 |
436572
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
36.8
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
18 |
436573
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
19
|
1
|
AO
|
Angola
|
2015
|
AO2015DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015-16
|
DHS
|
5405
|
5837
|
|
|
|
19 |
636245
|
SP/Fansidar use during pregnancy
|
0.1
|
1
|
BF
|
Burkina Faso
|
2003
|
BF2003DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2003
|
DHS
|
4201
|
4121
|
|
|
|
20 |
636246
|
SP/Fansidar 2+ doses during pregnancy
|
0
|
1
|
BF
|
Burkina Faso
|
2003
|
BF2003DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2003
|
DHS
|
4201
|
4121
|
|
|
|
21 |
636247
|
SP/Fansidar 3+ doses during pregnancy
|
0
|
1
|
BF
|
Burkina Faso
|
2003
|
BF2003DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2003
|
DHS
|
4201
|
4121
|
|
|
|
22 |
157531
|
SP/Fansidar use during pregnancy
|
73.8
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
23 |
157532
|
SP/Fansidar 2+ doses during pregnancy
|
38.5
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
24 |
157536
|
SP/Fansidar 3+ doses during pregnancy
|
5.2
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
25 |
157533
|
SP/Fansidar use during antenatal visit
|
71.1
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
26 |
157534
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
38.2
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
27 |
157535
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5
|
1
|
BF
|
Burkina Faso
|
2010
|
BF2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010
|
DHS
|
5988
|
5860
|
|
|
|
28 |
282365
|
SP/Fansidar use during pregnancy
|
67.7
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
29 |
282366
|
SP/Fansidar 2+ doses during pregnancy
|
48.3
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
30 |
282363
|
SP/Fansidar 3+ doses during pregnancy
|
23.1
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
31 |
282367
|
SP/Fansidar use during antenatal visit
|
65.4
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
32 |
282368
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
46.4
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
33 |
282389
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
22.2
|
1
|
BF
|
Burkina Faso
|
2014
|
BF2014MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014
|
MIS
|
2625
|
2673
|
|
|
|
34 |
706681
|
SP/Fansidar use during pregnancy
|
93.7
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
35 |
706682
|
SP/Fansidar 2+ doses during pregnancy
|
82.3
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
36 |
706680
|
SP/Fansidar 3+ doses during pregnancy
|
57.7
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
37 |
706683
|
SP/Fansidar use during antenatal visit
|
92.9
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
38 |
706684
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
81.6
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
39 |
706685
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
57.2
|
1
|
BF
|
Burkina Faso
|
2017
|
BF2017MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017-18
|
MIS
|
2402
|
2400
|
|
|
|
40 |
562628
|
SP/Fansidar use during pregnancy
|
92.8
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
41 |
562629
|
SP/Fansidar 2+ doses during pregnancy
|
79.1
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
42 |
562627
|
SP/Fansidar 3+ doses during pregnancy
|
56.8
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
43 |
562630
|
SP/Fansidar use during antenatal visit
|
91.6
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
44 |
562631
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
78.2
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
45 |
562634
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
56.3
|
1
|
BF
|
Burkina Faso
|
2021
|
BF2021DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
DHS
|
4684
|
4721
|
|
|
|
46 |
729781
|
SP/Fansidar use during pregnancy
|
4.9
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
47 |
729782
|
SP/Fansidar 2+ doses during pregnancy
|
3
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
48 |
729785
|
SP/Fansidar 3+ doses during pregnancy
|
1.2
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
49 |
729783
|
SP/Fansidar use during antenatal visit
|
0.2
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
50 |
729784
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.1
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
51 |
729786
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0
|
1
|
BJ
|
Benin
|
2006
|
BJ2006DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006
|
DHS
|
6380
|
6432
|
|
|
|
52 |
623028
|
SP/Fansidar use during pregnancy
|
42.3
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
53 |
623029
|
SP/Fansidar 2+ doses during pregnancy
|
25.2
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
54 |
623026
|
SP/Fansidar 3+ doses during pregnancy
|
10
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
55 |
623030
|
SP/Fansidar use during antenatal visit
|
37.3
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
56 |
623031
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
22.8
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
57 |
623025
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
8.8
|
1
|
BJ
|
Benin
|
2012
|
BJ2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011-12
|
DHS
|
5130
|
5178
|
|
|
|
58 |
669873
|
SP/Fansidar use during pregnancy
|
50.3
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
59 |
669874
|
SP/Fansidar 2+ doses during pregnancy
|
34.2
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
60 |
669878
|
SP/Fansidar 3+ doses during pregnancy
|
13.7
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
61 |
669875
|
SP/Fansidar use during antenatal visit
|
49.1
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
62 |
669876
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
33.4
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
63 |
669877
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
13.3
|
1
|
BJ
|
Benin
|
2017
|
BJ2017DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017-18
|
DHS
|
5502
|
5486
|
|
|
|
64 |
282780
|
SP/Fansidar use during pregnancy
|
0.3
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
65 |
282781
|
SP/Fansidar 2+ doses during pregnancy
|
0.3
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
66 |
282779
|
SP/Fansidar 3+ doses during pregnancy
|
0.3
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
67 |
282782
|
SP/Fansidar use during antenatal visit
|
0.1
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
68 |
282783
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.1
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
69 |
282784
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.1
|
1
|
BU
|
Burundi
|
2010
|
BU2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010
|
DHS
|
3111
|
3030
|
|
|
|
70 |
649104
|
SP/Fansidar use during pregnancy
|
0.1
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
71 |
649105
|
SP/Fansidar 2+ doses during pregnancy
|
0.1
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
72 |
649106
|
SP/Fansidar 3+ doses during pregnancy
|
0
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
73 |
649107
|
SP/Fansidar use during antenatal visit
|
0.1
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
74 |
649108
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.1
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
75 |
649109
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0
|
1
|
BU
|
Burundi
|
2012
|
BU2012MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
MIS
|
1786
|
1697
|
|
|
|
76 |
282940
|
SP/Fansidar use during pregnancy
|
29.6
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
77 |
282947
|
SP/Fansidar 2+ doses during pregnancy
|
20.7
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
78 |
282939
|
SP/Fansidar 3+ doses during pregnancy
|
12.9
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
79 |
282948
|
SP/Fansidar use during antenatal visit
|
29.1
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
80 |
282950
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
20.4
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
81 |
282952
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
12.6
|
1
|
BU
|
Burundi
|
2016
|
BU2016DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016-17
|
DHS
|
5412
|
5261
|
|
|
|
82 |
491798
|
SP/Fansidar use during pregnancy
|
16.2
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
83 |
491799
|
SP/Fansidar 2+ doses during pregnancy
|
6.9
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
84 |
491808
|
SP/Fansidar 3+ doses during pregnancy
|
2.5
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
85 |
491800
|
SP/Fansidar use during antenatal visit
|
12.1
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
86 |
491806
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
5.1
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
87 |
491807
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
1.9
|
1
|
CD
|
Congo Democratic Republic
|
2007
|
CD2007DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2007
|
DHS
|
3435
|
3515
|
|
|
|
88 |
638615
|
SP/Fansidar use during pregnancy
|
34.8
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
89 |
638616
|
SP/Fansidar 2+ doses during pregnancy
|
15
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
90 |
638620
|
SP/Fansidar 3+ doses during pregnancy
|
5.7
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
91 |
638617
|
SP/Fansidar use during antenatal visit
|
33
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
92 |
638618
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
14.3
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
93 |
638619
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5.4
|
1
|
CD
|
Congo Democratic Republic
|
2013
|
CD2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013-14
|
DHS
|
7168
|
7322
|
|
|
|
94 |
466064
|
SP/Fansidar use during pregnancy
|
2
|
1
|
CG
|
Congo
|
2005
|
CG2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005
|
DHS
|
2017
|
1980
|
|
|
|
95 |
283182
|
SP/Fansidar use during pregnancy
|
46.8
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
96 |
283183
|
SP/Fansidar 2+ doses during pregnancy
|
24.9
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
97 |
283188
|
SP/Fansidar 3+ doses during pregnancy
|
12.1
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
98 |
283184
|
SP/Fansidar use during antenatal visit
|
42.1
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
99 |
283186
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
22.2
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
100 |
283187
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.5
|
1
|
CG
|
Congo
|
2011
|
CG2011DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011-12
|
DHS
|
3426
|
3835
|
|
|
|
101 |
700256
|
SP/Fansidar use during pregnancy
|
29
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
102 |
700257
|
SP/Fansidar 2+ doses during pregnancy
|
20
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
103 |
700261
|
SP/Fansidar 3+ doses during pregnancy
|
8.1
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
104 |
700258
|
SP/Fansidar use during antenatal visit
|
25.9
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
105 |
700259
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
17.6
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
106 |
700260
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.6
|
1
|
CI
|
Cote d'Ivoire
|
2012
|
CI2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011-12
|
DHS
|
3039
|
3113
|
|
|
|
107 |
730304
|
SP/Fansidar use during pregnancy
|
79.8
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
108 |
730305
|
SP/Fansidar 2+ doses during pregnancy
|
58.3
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
109 |
730318
|
SP/Fansidar 3+ doses during pregnancy
|
34.6
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
110 |
730306
|
SP/Fansidar use during antenatal visit
|
77
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
111 |
730316
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
56.1
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
112 |
730317
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
33.1
|
1
|
CI
|
Cote d'Ivoire
|
2021
|
CI2021DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
DHS
|
3858
|
4184
|
|
|
|
113 |
132753
|
SP/Fansidar use during pregnancy
|
0.7
|
1
|
CM
|
Cameroon
|
2004
|
CM2004DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2004
|
DHS
|
3173
|
3184
|
|
|
|
114 |
647490
|
SP/Fansidar use during pregnancy
|
44
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
115 |
647491
|
SP/Fansidar 2+ doses during pregnancy
|
26.7
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
116 |
647489
|
SP/Fansidar 3+ doses during pregnancy
|
12
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
117 |
647486
|
SP/Fansidar use during antenatal visit
|
41.9
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
118 |
647487
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
25.6
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
119 |
647488
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
11.5
|
1
|
CM
|
Cameroon
|
2011
|
CM2011DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
DHS
|
4705
|
4702
|
|
|
|
120 |
539222
|
SP/Fansidar use during pregnancy
|
74.5
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
121 |
539223
|
SP/Fansidar 2+ doses during pregnancy
|
53.8
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
122 |
539221
|
SP/Fansidar 3+ doses during pregnancy
|
31.9
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
123 |
539224
|
SP/Fansidar use during antenatal visit
|
72.3
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
124 |
539226
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
52.2
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
125 |
539227
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
31.2
|
1
|
CM
|
Cameroon
|
2018
|
CM2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
3924
|
3788
|
|
|
|
126 |
161802
|
SP/Fansidar use during pregnancy
|
82.5
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
127 |
161804
|
SP/Fansidar 2+ doses during pregnancy
|
67.1
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
128 |
161803
|
SP/Fansidar 3+ doses during pregnancy
|
45.8
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
129 |
161805
|
SP/Fansidar use during antenatal visit
|
81
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
130 |
161806
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
65.8
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
131 |
161807
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
45.2
|
1
|
CM
|
Cameroon
|
2022
|
CM2022MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2022
|
MIS
|
1746
|
1740
|
|
|
|
132 |
79362
|
SP/Fansidar use during pregnancy
|
2.1
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
133 |
79363
|
SP/Fansidar 2+ doses during pregnancy
|
1.2
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
134 |
79361
|
SP/Fansidar 3+ doses during pregnancy
|
0.7
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
135 |
79364
|
SP/Fansidar use during antenatal visit
|
0.5
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
136 |
79365
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.3
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
137 |
79366
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.2
|
1
|
ET
|
Ethiopia
|
2005
|
ET2005DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2005
|
DHS
|
4321
|
3779
|
|
|
|
138 |
644452
|
SP/Fansidar use during pregnancy
|
19.5
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
139 |
644453
|
SP/Fansidar 2+ doses during pregnancy
|
13.1
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
140 |
644457
|
SP/Fansidar 3+ doses during pregnancy
|
6.8
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
141 |
644454
|
SP/Fansidar use during antenatal visit
|
18.6
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
142 |
644455
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
12.4
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
143 |
644456
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.3
|
1
|
GA
|
Gabon
|
2012
|
GA2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
DHS
|
2102
|
2511
|
|
|
|
144 |
445601
|
SP/Fansidar use during pregnancy
|
87.6
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
145 |
445602
|
SP/Fansidar 2+ doses during pregnancy
|
61.4
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
146 |
445600
|
SP/Fansidar 3+ doses during pregnancy
|
37.9
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
147 |
445603
|
SP/Fansidar use during antenatal visit
|
69
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
148 |
445618
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
50.7
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
149 |
445619
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
30.9
|
1
|
GA
|
Gabon
|
2019
|
GA2019DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019-21
|
DHS
|
2456
|
2519
|
|
|
|
150 |
284235
|
SP/Fansidar use during pregnancy
|
1.1
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
151 |
284236
|
SP/Fansidar 2+ doses during pregnancy
|
1
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
152 |
284250
|
SP/Fansidar 3+ doses during pregnancy
|
0.8
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
153 |
284237
|
SP/Fansidar use during antenatal visit
|
0.8
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
154 |
284238
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.8
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
155 |
284249
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.6
|
1
|
GH
|
Ghana
|
2003
|
GH2003DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2003
|
DHS
|
1421
|
1519
|
|
|
|
156 |
211169
|
SP/Fansidar use during pregnancy
|
58.2
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
157 |
211170
|
SP/Fansidar 2+ doses during pregnancy
|
45.5
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
158 |
211168
|
SP/Fansidar 3+ doses during pregnancy
|
28
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
159 |
211171
|
SP/Fansidar use during antenatal visit
|
56
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
160 |
211173
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
43.7
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
161 |
211174
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
26.8
|
1
|
GH
|
Ghana
|
2008
|
GH2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008
|
DHS
|
1178
|
1225
|
|
|
|
162 |
27735
|
SP/Fansidar use during pregnancy
|
82.9
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
163 |
27740
|
SP/Fansidar 2+ doses during pregnancy
|
67.7
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
164 |
27744
|
SP/Fansidar 3+ doses during pregnancy
|
38.6
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
165 |
27741
|
SP/Fansidar use during antenatal visit
|
82.5
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
166 |
27742
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
67.5
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
167 |
27743
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
38.5
|
1
|
GH
|
Ghana
|
2014
|
GH2014DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014
|
DHS
|
2264
|
2329
|
|
|
|
168 |
44635
|
SP/Fansidar use during pregnancy
|
85.3
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
169 |
44636
|
SP/Fansidar 2+ doses during pregnancy
|
78
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
170 |
44640
|
SP/Fansidar 3+ doses during pregnancy
|
59.6
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
171 |
44637
|
SP/Fansidar use during antenatal visit
|
85.3
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
172 |
44638
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
78
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
173 |
44639
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
59.6
|
1
|
GH
|
Ghana
|
2016
|
GH2016MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
MIS
|
1285
|
1291
|
|
|
|
174 |
452709
|
SP/Fansidar use during pregnancy
|
91.4
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
175 |
452710
|
SP/Fansidar 2+ doses during pregnancy
|
80.2
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
176 |
452712
|
SP/Fansidar 3+ doses during pregnancy
|
61
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
177 |
452711
|
SP/Fansidar use during antenatal visit
|
91.1
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
178 |
452713
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
79.9
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
179 |
452714
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
60.9
|
1
|
GH
|
Ghana
|
2019
|
GH2019MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019
|
MIS
|
1151
|
1215
|
|
|
|
180 |
718823
|
SP/Fansidar use during pregnancy
|
90
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
181 |
718824
|
SP/Fansidar 2+ doses during pregnancy
|
77.5
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
182 |
718822
|
SP/Fansidar 3+ doses during pregnancy
|
60.2
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
183 |
718825
|
SP/Fansidar use during antenatal visit
|
89.1
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
184 |
718844
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
76.9
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
185 |
718845
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
59.8
|
1
|
GH
|
Ghana
|
2022
|
GH2022DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2022
|
DHS
|
3491
|
3850
|
|
|
|
186 |
284531
|
SP/Fansidar use during pregnancy
|
93.5
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
187 |
284532
|
SP/Fansidar 2+ doses during pregnancy
|
63
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
188 |
284526
|
SP/Fansidar 3+ doses during pregnancy
|
5.7
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
189 |
284544
|
SP/Fansidar use during antenatal visit
|
92.3
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
190 |
284545
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
62.3
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
191 |
284546
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5.7
|
1
|
GM
|
Gambia
|
2013
|
GM2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
DHS
|
3392
|
3481
|
|
|
|
192 |
638888
|
SP/Fansidar use during pregnancy
|
97.7
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
193 |
638889
|
SP/Fansidar 2+ doses during pregnancy
|
79.7
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
194 |
638893
|
SP/Fansidar 3+ doses during pregnancy
|
52.2
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
195 |
638890
|
SP/Fansidar use during antenatal visit
|
97.5
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
196 |
638891
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
79.7
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
197 |
638894
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
52.2
|
1
|
GM
|
Gambia
|
2019
|
GM2019DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019-20
|
DHS
|
3129
|
3441
|
|
|
|
198 |
710849
|
SP/Fansidar use during pregnancy
|
4.1
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
199 |
710850
|
SP/Fansidar 2+ doses during pregnancy
|
3.6
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
200 |
710854
|
SP/Fansidar 3+ doses during pregnancy
|
2.8
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
201 |
710851
|
SP/Fansidar use during antenatal visit
|
3.7
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
202 |
710852
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
3.2
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
203 |
710853
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
2.4
|
1
|
GN
|
Guinea
|
2005
|
GN2005DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2005
|
DHS
|
2614
|
2586
|
|
|
|
204 |
773701
|
SP/Fansidar use during pregnancy
|
31.7
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
205 |
773702
|
SP/Fansidar 2+ doses during pregnancy
|
22.5
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
206 |
773700
|
SP/Fansidar 3+ doses during pregnancy
|
11.2
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
207 |
773703
|
SP/Fansidar use during antenatal visit
|
30.8
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
208 |
773704
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
22
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
209 |
773705
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.9
|
1
|
GN
|
Guinea
|
2012
|
GN2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
DHS
|
2818
|
2810
|
|
|
|
210 |
20935
|
SP/Fansidar use during pregnancy
|
80
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
211 |
20936
|
SP/Fansidar 2+ doses during pregnancy
|
62.7
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
212 |
20941
|
SP/Fansidar 3+ doses during pregnancy
|
35.7
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
213 |
20938
|
SP/Fansidar use during antenatal visit
|
79.6
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
214 |
20939
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
62.4
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
215 |
20940
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
35.6
|
1
|
GN
|
Guinea
|
2018
|
GN2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
3026
|
3066
|
|
|
|
216 |
761713
|
SP/Fansidar use during pregnancy
|
89.3
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
217 |
761714
|
SP/Fansidar 2+ doses during pregnancy
|
74.4
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
218 |
761712
|
SP/Fansidar 3+ doses during pregnancy
|
50.3
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
219 |
761715
|
SP/Fansidar use during antenatal visit
|
86.8
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
220 |
761716
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
72.5
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
221 |
761717
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
48.7
|
1
|
GN
|
Guinea
|
2021
|
GN2021MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
MIS
|
1510
|
1511
|
|
|
|
222 |
284680
|
SP/Fansidar use during pregnancy
|
0.2
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
223 |
284681
|
SP/Fansidar 2+ doses during pregnancy
|
0.1
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
224 |
284678
|
SP/Fansidar 3+ doses during pregnancy
|
0.1
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
225 |
284682
|
SP/Fansidar use during antenatal visit
|
0.1
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
226 |
284683
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.1
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
227 |
284684
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.1
|
1
|
GY
|
Guyana
|
2009
|
GY2009DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2009
|
DHS
|
750
|
869
|
|
|
|
228 |
285147
|
SP/Fansidar use during pregnancy
|
14.5
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
229 |
285148
|
SP/Fansidar 2+ doses during pregnancy
|
6.8
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
230 |
285156
|
SP/Fansidar 3+ doses during pregnancy
|
3.1
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
231 |
285149
|
SP/Fansidar use during antenatal visit
|
9.9
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
232 |
285150
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
4.5
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
233 |
285154
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
1.9
|
1
|
KE
|
Kenya
|
2003
|
KE2003DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2003
|
DHS
|
2416
|
2357
|
|
|
|
234 |
143584
|
SP/Fansidar use during pregnancy
|
35.5
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
235 |
143585
|
SP/Fansidar 2+ doses during pregnancy
|
15.1
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
236 |
143603
|
SP/Fansidar 3+ doses during pregnancy
|
6.9
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
237 |
143600
|
SP/Fansidar use during antenatal visit
|
33.6
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
238 |
143601
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
14
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
239 |
143602
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.2
|
1
|
KE
|
Kenya
|
2008
|
KE2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008-09
|
DHS
|
2264
|
2373
|
|
|
|
240 |
133413
|
SP/Fansidar use during pregnancy
|
30.4
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
241 |
133414
|
SP/Fansidar 2+ doses during pregnancy
|
17.2
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
242 |
133412
|
SP/Fansidar 3+ doses during pregnancy
|
10.3
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
243 |
133415
|
SP/Fansidar use during antenatal visit
|
29.6
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
244 |
133416
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
16.9
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
245 |
133417
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.1
|
1
|
KE
|
Kenya
|
2014
|
KE2014DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014
|
DHS
|
7357
|
7925
|
|
|
|
246 |
764719
|
SP/Fansidar use during pregnancy
|
52.6
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
247 |
764721
|
SP/Fansidar 2+ doses during pregnancy
|
35.9
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
248 |
764720
|
SP/Fansidar 3+ doses during pregnancy
|
22.9
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
249 |
764722
|
SP/Fansidar use during antenatal visit
|
50.8
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
250 |
764723
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
34.7
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
251 |
764724
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
21.9
|
1
|
KE
|
Kenya
|
2015
|
KE2015MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015
|
MIS
|
1268
|
1385
|
|
|
|
252 |
341687
|
SP/Fansidar use during pregnancy
|
37.8
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
253 |
341688
|
SP/Fansidar 2+ doses during pregnancy
|
29.9
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
254 |
341695
|
SP/Fansidar 3+ doses during pregnancy
|
22
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
255 |
341689
|
SP/Fansidar use during antenatal visit
|
37
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
256 |
341692
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
29.5
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
257 |
341693
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
21.8
|
1
|
KE
|
Kenya
|
2020
|
KE2020MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2020
|
MIS
|
1363
|
1481
|
|
|
|
258 |
692882
|
SP/Fansidar use during pregnancy
|
28.2
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
259 |
692883
|
SP/Fansidar 2+ doses during pregnancy
|
19.8
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
260 |
692887
|
SP/Fansidar 3+ doses during pregnancy
|
12.5
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
261 |
692884
|
SP/Fansidar use during antenatal visit
|
27.1
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
262 |
692885
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
19.3
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
263 |
692886
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
12.4
|
1
|
KE
|
Kenya
|
2022
|
KE2022DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2022
|
DHS
|
3523
|
3985
|
|
|
|
264 |
600276
|
SP/Fansidar use during pregnancy
|
50.8
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
265 |
600280
|
SP/Fansidar 2+ doses during pregnancy
|
30.8
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
266 |
600279
|
SP/Fansidar 3+ doses during pregnancy
|
11
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
267 |
600281
|
SP/Fansidar use during antenatal visit
|
46.4
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
268 |
600282
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
27.8
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
269 |
600283
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
9.9
|
1
|
KM
|
Comoros
|
2012
|
KM2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
DHS
|
1298
|
1255
|
|
|
|
270 |
733487
|
SP/Fansidar use during pregnancy
|
57.9
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
271 |
733488
|
SP/Fansidar 2+ doses during pregnancy
|
47.4
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
272 |
733492
|
SP/Fansidar 3+ doses during pregnancy
|
11
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
273 |
733489
|
SP/Fansidar use during antenatal visit
|
55.2
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
274 |
733490
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
45.1
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
275 |
733491
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.3
|
1
|
LB
|
Liberia
|
2009
|
LB2009MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2009
|
MIS
|
1573
|
1644
|
|
|
|
276 |
150729
|
SP/Fansidar use during pregnancy
|
63.2
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
277 |
150730
|
SP/Fansidar 2+ doses during pregnancy
|
50.3
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
278 |
150735
|
SP/Fansidar 3+ doses during pregnancy
|
26.5
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
279 |
150731
|
SP/Fansidar use during antenatal visit
|
62
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
280 |
150732
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
49.6
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
281 |
150733
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
26.1
|
1
|
LB
|
Liberia
|
2011
|
LB2011MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
MIS
|
1230
|
1326
|
|
|
|
282 |
285839
|
SP/Fansidar use during pregnancy
|
68.1
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
283 |
285840
|
SP/Fansidar 2+ doses during pregnancy
|
50.2
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
284 |
285825
|
SP/Fansidar 3+ doses during pregnancy
|
17.9
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
285 |
285841
|
SP/Fansidar use during antenatal visit
|
64.8
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
286 |
285842
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
47.6
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
287 |
285843
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
17.1
|
1
|
LB
|
Liberia
|
2013
|
LB2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
DHS
|
2650
|
3064
|
|
|
|
288 |
41416
|
SP/Fansidar use during pregnancy
|
84.8
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
289 |
41411
|
SP/Fansidar 2+ doses during pregnancy
|
55.8
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
290 |
41415
|
SP/Fansidar 3+ doses during pregnancy
|
23.1
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
291 |
41412
|
SP/Fansidar use during antenatal visit
|
82.4
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
292 |
41413
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
54.5
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
293 |
41414
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
22.2
|
1
|
LB
|
Liberia
|
2016
|
LB2016MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
MIS
|
1146
|
1219
|
|
|
|
294 |
665171
|
SP/Fansidar use during pregnancy
|
90.3
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
295 |
665172
|
SP/Fansidar 2+ doses during pregnancy
|
70.1
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
296 |
665176
|
SP/Fansidar 3+ doses during pregnancy
|
40.3
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
297 |
665173
|
SP/Fansidar use during antenatal visit
|
88.9
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
298 |
665174
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
69.2
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
299 |
665175
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
40
|
1
|
LB
|
Liberia
|
2019
|
LB2019DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019-20
|
DHS
|
2096
|
2284
|
|
|
|
300 |
618418
|
SP/Fansidar use during pregnancy
|
93.4
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
301 |
618419
|
SP/Fansidar 2+ doses during pregnancy
|
79.9
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
302 |
618417
|
SP/Fansidar 3+ doses during pregnancy
|
62.6
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
303 |
618420
|
SP/Fansidar use during antenatal visit
|
92.7
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
304 |
618421
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
79.5
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
305 |
618422
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
62.4
|
1
|
LB
|
Liberia
|
2022
|
LB2022MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2022
|
MIS
|
1109
|
1171
|
|
|
|
306 |
285893
|
SP/Fansidar use during pregnancy
|
11.8
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
307 |
285894
|
SP/Fansidar 2+ doses during pregnancy
|
6.7
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
308 |
285913
|
SP/Fansidar 3+ doses during pregnancy
|
1.9
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
309 |
285895
|
SP/Fansidar use during antenatal visit
|
11
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
310 |
285909
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
6.4
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
311 |
285911
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
1.8
|
1
|
MD
|
Madagascar
|
2008
|
MD2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008-09
|
DHS
|
4807
|
4704
|
|
|
|
312 |
452526
|
SP/Fansidar use during pregnancy
|
31.6
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
313 |
452527
|
SP/Fansidar 2+ doses during pregnancy
|
19.5
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
314 |
452525
|
SP/Fansidar 3+ doses during pregnancy
|
4.8
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
315 |
452539
|
SP/Fansidar use during antenatal visit
|
30.6
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
316 |
452540
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
19.5
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
317 |
452541
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
4.8
|
1
|
MD
|
Madagascar
|
2011
|
MD2011MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
MIS
|
2477
|
2292
|
|
|
|
318 |
589152
|
SP/Fansidar use during pregnancy
|
30
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
319 |
589153
|
SP/Fansidar 2+ doses during pregnancy
|
18.4
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
320 |
589158
|
SP/Fansidar 3+ doses during pregnancy
|
3.9
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
321 |
589154
|
SP/Fansidar use during antenatal visit
|
29.3
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
322 |
589155
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
18.2
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
323 |
589157
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.9
|
1
|
MD
|
Madagascar
|
2013
|
MD2013MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
MIS
|
2129
|
2160
|
|
|
|
324 |
465828
|
SP/Fansidar use during pregnancy
|
38.4
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
325 |
465829
|
SP/Fansidar 2+ doses during pregnancy
|
23
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
326 |
465833
|
SP/Fansidar 3+ doses during pregnancy
|
10.6
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
327 |
465830
|
SP/Fansidar use during antenatal visit
|
37.4
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
328 |
465831
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
22.3
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
329 |
465832
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.3
|
1
|
MD
|
Madagascar
|
2016
|
MD2016MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
MIS
|
2786
|
2732
|
|
|
|
330 |
441733
|
SP/Fansidar use during pregnancy
|
50.9
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
331 |
441749
|
SP/Fansidar 2+ doses during pregnancy
|
41.2
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
332 |
441732
|
SP/Fansidar 3+ doses during pregnancy
|
31
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
333 |
441750
|
SP/Fansidar use during antenatal visit
|
49.6
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
334 |
441751
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
40.2
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
335 |
441752
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
30.2
|
1
|
MD
|
Madagascar
|
2021
|
MD2021DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
DHS
|
4897
|
4946
|
|
|
|
336 |
82157
|
SP/Fansidar use during pregnancy
|
16.1
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
337 |
82158
|
SP/Fansidar 2+ doses during pregnancy
|
11.2
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
338 |
82162
|
SP/Fansidar 3+ doses during pregnancy
|
5.9
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
339 |
82159
|
SP/Fansidar use during antenatal visit
|
14.1
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
340 |
82160
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
9.9
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
341 |
82161
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5
|
1
|
ML
|
Mali
|
2006
|
ML2006DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006
|
DHS
|
5663
|
5581
|
|
|
|
342 |
608230
|
SP/Fansidar use during pregnancy
|
56.2
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
343 |
608231
|
SP/Fansidar 2+ doses during pregnancy
|
30
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
344 |
608229
|
SP/Fansidar 3+ doses during pregnancy
|
11.8
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
345 |
608232
|
SP/Fansidar use during antenatal visit
|
48.8
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
346 |
608233
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
28.5
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
347 |
608234
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
11.1
|
1
|
ML
|
Mali
|
2012
|
ML2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012-13
|
DHS
|
3965
|
3952
|
|
|
|
348 |
515040
|
SP/Fansidar use during pregnancy
|
66.4
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
349 |
515041
|
SP/Fansidar 2+ doses during pregnancy
|
44.4
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
350 |
515046
|
SP/Fansidar 3+ doses during pregnancy
|
21
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
351 |
515042
|
SP/Fansidar use during antenatal visit
|
56
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
352 |
515044
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
37.8
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
353 |
515045
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
17.8
|
1
|
ML
|
Mali
|
2015
|
ML2015MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015
|
MIS
|
3017
|
3007
|
|
|
|
354 |
452312
|
SP/Fansidar use during pregnancy
|
74.2
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
355 |
452313
|
SP/Fansidar 2+ doses during pregnancy
|
55.4
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
356 |
452317
|
SP/Fansidar 3+ doses during pregnancy
|
28.3
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
357 |
452314
|
SP/Fansidar use during antenatal visit
|
69
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
358 |
452315
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
51.4
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
359 |
452316
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
26.4
|
1
|
ML
|
Mali
|
2018
|
ML2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
4150
|
3926
|
|
|
|
360 |
335985
|
SP/Fansidar use during pregnancy
|
78.2
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
361 |
335986
|
SP/Fansidar 2+ doses during pregnancy
|
56
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
362 |
336011
|
SP/Fansidar 3+ doses during pregnancy
|
34.4
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
363 |
335987
|
SP/Fansidar use during antenatal visit
|
75.4
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
364 |
336009
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
54.7
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
365 |
336010
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
33.8
|
1
|
ML
|
Mali
|
2021
|
ML2021MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
MIS
|
3665
|
3553
|
|
|
|
366 |
53786
|
SP/Fansidar use during pregnancy
|
54.5
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
367 |
53797
|
SP/Fansidar 2+ doses during pregnancy
|
23.2
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
368 |
53785
|
SP/Fansidar 3+ doses during pregnancy
|
10.2
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
369 |
53798
|
SP/Fansidar use during antenatal visit
|
53.2
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
370 |
53803
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
22.9
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
371 |
53804
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.1
|
1
|
MR
|
Mauritania
|
2020
|
MR2020DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019-21
|
DHS
|
4485
|
4465
|
|
|
|
372 |
692496
|
SP/Fansidar use during pregnancy
|
78.7
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
373 |
692497
|
SP/Fansidar 2+ doses during pregnancy
|
46.5
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
374 |
692490
|
SP/Fansidar 3+ doses during pregnancy
|
14.7
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
375 |
692489
|
SP/Fansidar use during antenatal visit
|
72.9
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
376 |
692491
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
42.9
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
377 |
692492
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
13.7
|
1
|
MW
|
Malawi
|
2004
|
MW2004DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2004
|
DHS
|
4604
|
4662
|
|
|
|
378 |
204783
|
SP/Fansidar use during pregnancy
|
87.6
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
379 |
204784
|
SP/Fansidar 2+ doses during pregnancy
|
55
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
380 |
204786
|
SP/Fansidar 3+ doses during pregnancy
|
18.2
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
381 |
204785
|
SP/Fansidar use during antenatal visit
|
85.8
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
382 |
204787
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
53.8
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
383 |
204788
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
17.8
|
1
|
MW
|
Malawi
|
2010
|
MW2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010
|
DHS
|
7724
|
7755
|
|
|
|
384 |
287002
|
SP/Fansidar use during pregnancy
|
77.4
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
385 |
287003
|
SP/Fansidar 2+ doses during pregnancy
|
53.8
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
386 |
287016
|
SP/Fansidar 3+ doses during pregnancy
|
12.7
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
387 |
287004
|
SP/Fansidar use during antenatal visit
|
76.2
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
388 |
287005
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
53.2
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
389 |
287015
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
12.7
|
1
|
MW
|
Malawi
|
2012
|
MW2012MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
MIS
|
990
|
921
|
|
|
|
390 |
287107
|
SP/Fansidar use during pregnancy
|
90.3
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
391 |
287108
|
SP/Fansidar 2+ doses during pregnancy
|
64.4
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
392 |
287106
|
SP/Fansidar 3+ doses during pregnancy
|
12.6
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
393 |
287109
|
SP/Fansidar use during antenatal visit
|
88.7
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
394 |
287110
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
63.3
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
395 |
287113
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
11.9
|
1
|
MW
|
Malawi
|
2014
|
MW2014MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014
|
MIS
|
946
|
884
|
|
|
|
396 |
129611
|
SP/Fansidar use during pregnancy
|
90.5
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
397 |
129612
|
SP/Fansidar 2+ doses during pregnancy
|
64.1
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
398 |
129616
|
SP/Fansidar 3+ doses during pregnancy
|
30.4
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
399 |
129613
|
SP/Fansidar use during antenatal visit
|
89.3
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
400 |
129614
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
63.4
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
401 |
129615
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
30
|
1
|
MW
|
Malawi
|
2015
|
MW2015DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015-16
|
DHS
|
6693
|
6683
|
|
|
|
402 |
118472
|
SP/Fansidar use during pregnancy
|
91.8
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
403 |
118473
|
SP/Fansidar 2+ doses during pregnancy
|
76.1
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
404 |
118477
|
SP/Fansidar 3+ doses during pregnancy
|
41.1
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
405 |
118474
|
SP/Fansidar use during antenatal visit
|
91.5
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
406 |
118475
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
75.8
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
407 |
118476
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
40.9
|
1
|
MW
|
Malawi
|
2017
|
MW2017MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017
|
MIS
|
1032
|
938
|
|
|
|
408 |
578137
|
SP/Fansidar use during pregnancy
|
37.2
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
409 |
578138
|
SP/Fansidar 2+ doses during pregnancy
|
19.6
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
410 |
578142
|
SP/Fansidar 3+ doses during pregnancy
|
9.5
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
411 |
578139
|
SP/Fansidar use during antenatal visit
|
34.9
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
412 |
578140
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
18.6
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
413 |
578141
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
9.2
|
1
|
MZ
|
Mozambique
|
2011
|
MZ2011DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
DHS
|
4913
|
4612
|
|
|
|
414 |
287603
|
SP/Fansidar use during pregnancy
|
54.4
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
415 |
287604
|
SP/Fansidar 2+ doses during pregnancy
|
35.8
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
416 |
287611
|
SP/Fansidar 3+ doses during pregnancy
|
23.3
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
417 |
287605
|
SP/Fansidar use during antenatal visit
|
51.4
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
418 |
287621
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
34.2
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
419 |
287622
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
22.4
|
1
|
MZ
|
Mozambique
|
2015
|
MZ2015AIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015
|
AIS
|
2257
|
2083
|
|
|
|
420 |
775977
|
SP/Fansidar use during pregnancy
|
84.2
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
421 |
775978
|
SP/Fansidar 2+ doses during pregnancy
|
60.8
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
422 |
775984
|
SP/Fansidar 3+ doses during pregnancy
|
40.6
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
423 |
775979
|
SP/Fansidar use during antenatal visit
|
83.2
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
424 |
775982
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
60.4
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
425 |
775983
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
40.2
|
1
|
MZ
|
Mozambique
|
2018
|
MZ2018MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
MIS
|
2039
|
1898
|
|
|
|
426 |
287750
|
SP/Fansidar use during pregnancy
|
1.3
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
427 |
287751
|
SP/Fansidar 2+ doses during pregnancy
|
1.1
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
428 |
287752
|
SP/Fansidar 3+ doses during pregnancy
|
0.5
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
429 |
287753
|
SP/Fansidar use during antenatal visit
|
0.8
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
430 |
287754
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.7
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
431 |
287755
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.4
|
1
|
NG
|
Nigeria
|
2003
|
NG2003DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2003
|
DHS
|
2447
|
2395
|
|
|
|
432 |
287805
|
SP/Fansidar use during pregnancy
|
10.9
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
433 |
287806
|
SP/Fansidar 2+ doses during pregnancy
|
6.5
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
434 |
287810
|
SP/Fansidar 3+ doses during pregnancy
|
3.2
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
435 |
287807
|
SP/Fansidar use during antenatal visit
|
8
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
436 |
287808
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
4.9
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
437 |
287809
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
2.4
|
1
|
NG
|
Nigeria
|
2008
|
NG2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008
|
DHS
|
11027
|
11228
|
|
|
|
438 |
287837
|
SP/Fansidar use during pregnancy
|
20.2
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
439 |
287838
|
SP/Fansidar 2+ doses during pregnancy
|
14.6
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
440 |
287854
|
SP/Fansidar 3+ doses during pregnancy
|
5.7
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
441 |
287839
|
SP/Fansidar use during antenatal visit
|
17.4
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
442 |
287840
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
13.2
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
443 |
287841
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5.1
|
1
|
NG
|
Nigeria
|
2010
|
NG2010MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010
|
MIS
|
2255
|
2170
|
|
|
|
444 |
39292
|
SP/Fansidar use during pregnancy
|
27.3
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
445 |
39293
|
SP/Fansidar 2+ doses during pregnancy
|
17.4
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
446 |
39291
|
SP/Fansidar 3+ doses during pregnancy
|
7.1
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
447 |
39294
|
SP/Fansidar use during antenatal visit
|
22.6
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
448 |
39287
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
14.6
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
449 |
39288
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5.8
|
1
|
NG
|
Nigeria
|
2013
|
NG2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
DHS
|
12473
|
12397
|
|
|
|
450 |
763248
|
SP/Fansidar use during pregnancy
|
51.4
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
451 |
763249
|
SP/Fansidar 2+ doses during pregnancy
|
40.9
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
452 |
763253
|
SP/Fansidar 3+ doses during pregnancy
|
21.4
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
453 |
763250
|
SP/Fansidar use during antenatal visit
|
46.6
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
454 |
763251
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
37.2
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
455 |
763252
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
19
|
1
|
NG
|
Nigeria
|
2015
|
NG2015MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015
|
MIS
|
2522
|
2490
|
|
|
|
456 |
452363
|
SP/Fansidar use during pregnancy
|
63.6
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
457 |
452364
|
SP/Fansidar 2+ doses during pregnancy
|
40.4
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
458 |
452369
|
SP/Fansidar 3+ doses during pregnancy
|
16.6
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
459 |
452365
|
SP/Fansidar use during antenatal visit
|
56.7
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
460 |
452366
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
36
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
461 |
452368
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
14.6
|
1
|
NG
|
Nigeria
|
2018
|
NG2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
12935
|
12818
|
|
|
|
462 |
153017
|
SP/Fansidar use during pregnancy
|
58.9
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
463 |
153018
|
SP/Fansidar 2+ doses during pregnancy
|
45.9
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
464 |
153016
|
SP/Fansidar 3+ doses during pregnancy
|
31
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
465 |
153019
|
SP/Fansidar use during antenatal visit
|
56
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
466 |
153020
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
43.7
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
467 |
153021
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
29.5
|
1
|
NG
|
Nigeria
|
2021
|
NG2021MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
MIS
|
4087
|
3928
|
|
|
|
468 |
77364
|
SP/Fansidar use during pregnancy
|
0.5
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
469 |
77365
|
SP/Fansidar 2+ doses during pregnancy
|
0.5
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
470 |
77385
|
SP/Fansidar 3+ doses during pregnancy
|
0.4
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
471 |
77366
|
SP/Fansidar use during antenatal visit
|
0.4
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
472 |
77367
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.4
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
473 |
77368
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.3
|
1
|
NI
|
Niger
|
2006
|
NI2006DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006
|
DHS
|
3918
|
3613
|
|
|
|
474 |
185075
|
SP/Fansidar use during pregnancy
|
62.7
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
475 |
185076
|
SP/Fansidar 2+ doses during pregnancy
|
36.9
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
476 |
185081
|
SP/Fansidar 3+ doses during pregnancy
|
9.1
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
477 |
185077
|
SP/Fansidar use during antenatal visit
|
59.4
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
478 |
185078
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
34.8
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
479 |
185079
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
8.6
|
1
|
NI
|
Niger
|
2012
|
NI2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012
|
DHS
|
5143
|
4759
|
|
|
|
480 |
287672
|
SP/Fansidar use during pregnancy
|
81.6
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
481 |
287673
|
SP/Fansidar 2+ doses during pregnancy
|
56.2
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
482 |
287670
|
SP/Fansidar 3+ doses during pregnancy
|
25
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
483 |
287674
|
SP/Fansidar use during antenatal visit
|
80.7
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
484 |
287675
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
55.8
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
485 |
287676
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
24.9
|
1
|
NI
|
Niger
|
2021
|
NI2021MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2021
|
MIS
|
2066
|
1989
|
|
|
|
486 |
113296
|
SP/Fansidar use during pregnancy
|
27.8
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
487 |
113297
|
SP/Fansidar 2+ doses during pregnancy
|
10.6
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
488 |
113306
|
SP/Fansidar 3+ doses during pregnancy
|
7
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
489 |
113298
|
SP/Fansidar use during antenatal visit
|
19.6
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
490 |
113299
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
10
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
491 |
113304
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.7
|
1
|
NM
|
Namibia
|
2006
|
NM2006DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006-07
|
DHS
|
2054
|
2135
|
|
|
|
492 |
772436
|
SP/Fansidar use during pregnancy
|
9.1
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
493 |
772437
|
SP/Fansidar 2+ doses during pregnancy
|
5.1
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
494 |
772444
|
SP/Fansidar 3+ doses during pregnancy
|
3.4
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
495 |
772438
|
SP/Fansidar use during antenatal visit
|
7.5
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
496 |
772439
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
4.9
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
497 |
772443
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.3
|
1
|
NM
|
Namibia
|
2013
|
NM2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
DHS
|
1947
|
2051
|
|
|
|
498 |
19961
|
SP/Fansidar use during pregnancy
|
50.2
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
499 |
19962
|
SP/Fansidar 2+ doses during pregnancy
|
35.7
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
500 |
19966
|
SP/Fansidar 3+ doses during pregnancy
|
23.5
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
501 |
19963
|
SP/Fansidar use during antenatal visit
|
48.1
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
502 |
19964
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
35
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
503 |
19965
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
23
|
1
|
PG
|
Papua New Guinea
|
2017
|
PG2017DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016-18
|
DHS
|
3642
|
3605
|
|
|
|
504 |
719205
|
SP/Fansidar use during pregnancy
|
1.6
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
505 |
719206
|
SP/Fansidar 2+ doses during pregnancy
|
0.9
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
506 |
719211
|
SP/Fansidar 3+ doses during pregnancy
|
0.5
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
507 |
719207
|
SP/Fansidar use during antenatal visit
|
0.4
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
508 |
719208
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
0.2
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
509 |
719209
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
0.1
|
1
|
RW
|
Rwanda
|
2005
|
RW2005DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2005
|
DHS
|
3436
|
3412
|
|
|
|
510 |
676559
|
SP/Fansidar use during pregnancy
|
53
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
511 |
676560
|
SP/Fansidar 2+ doses during pregnancy
|
17.7
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
512 |
676577
|
SP/Fansidar 3+ doses during pregnancy
|
3.7
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
513 |
676561
|
SP/Fansidar use during antenatal visit
|
51.3
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
514 |
676575
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
17.2
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
515 |
676576
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.5
|
1
|
RW
|
Rwanda
|
2008
|
RW2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2007-08
|
DHS
|
2267
|
2184
|
|
|
|
516 |
244130
|
SP/Fansidar use during pregnancy
|
19.5
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
517 |
244133
|
SP/Fansidar 2+ doses during pregnancy
|
12
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
518 |
244129
|
SP/Fansidar 3+ doses during pregnancy
|
5.2
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
519 |
244134
|
SP/Fansidar use during antenatal visit
|
16.8
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
520 |
244135
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
10.3
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
521 |
244136
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
4.7
|
1
|
SL
|
Sierra Leone
|
2008
|
SL2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008
|
DHS
|
2478
|
2410
|
|
|
|
522 |
631122
|
SP/Fansidar use during pregnancy
|
64.8
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
523 |
631123
|
SP/Fansidar 2+ doses during pregnancy
|
46.9
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
524 |
631129
|
SP/Fansidar 3+ doses during pregnancy
|
20.7
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
525 |
631125
|
SP/Fansidar use during antenatal visit
|
62.1
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
526 |
631127
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
45.1
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
527 |
631128
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
19.7
|
1
|
SL
|
Sierra Leone
|
2013
|
SL2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013
|
DHS
|
4820
|
4668
|
|
|
|
528 |
459029
|
SP/Fansidar use during pregnancy
|
90.6
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
529 |
459030
|
SP/Fansidar 2+ doses during pregnancy
|
71.6
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
530 |
459037
|
SP/Fansidar 3+ doses during pregnancy
|
31.1
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
531 |
459031
|
SP/Fansidar use during antenatal visit
|
90.3
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
532 |
459032
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
71.3
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
533 |
459036
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
31
|
1
|
SL
|
Sierra Leone
|
2016
|
SL2016MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
MIS
|
2451
|
2554
|
|
|
|
534 |
742228
|
SP/Fansidar use during pregnancy
|
93.5
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
535 |
742229
|
SP/Fansidar 2+ doses during pregnancy
|
73.8
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
536 |
742233
|
SP/Fansidar 3+ doses during pregnancy
|
35.7
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
537 |
742230
|
SP/Fansidar use during antenatal visit
|
92.2
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
538 |
742231
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
73
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
539 |
742232
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
35.2
|
1
|
SL
|
Sierra Leone
|
2019
|
SL2019DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019
|
DHS
|
3950
|
3970
|
|
|
|
540 |
89594
|
SP/Fansidar use during pregnancy
|
23.5
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
541 |
89595
|
SP/Fansidar 2+ doses during pregnancy
|
13.2
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
542 |
89597
|
SP/Fansidar 3+ doses during pregnancy
|
3.8
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
543 |
89596
|
SP/Fansidar use during antenatal visit
|
20.6
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
544 |
89598
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
11.9
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
545 |
89605
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.4
|
1
|
SN
|
Senegal
|
2005
|
SN2005DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2005
|
DHS
|
4391
|
4551
|
|
|
|
546 |
138756
|
SP/Fansidar use during pregnancy
|
71.8
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
547 |
138757
|
SP/Fansidar 2+ doses during pregnancy
|
51.2
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
548 |
138761
|
SP/Fansidar 3+ doses during pregnancy
|
7
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
549 |
138758
|
SP/Fansidar use during antenatal visit
|
68.7
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
550 |
138759
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
49.3
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
551 |
138760
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.7
|
1
|
SN
|
Senegal
|
2006
|
SN2006MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006
|
MIS
|
1906
|
1963
|
|
|
|
552 |
484124
|
SP/Fansidar use during pregnancy
|
78.1
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
553 |
484126
|
SP/Fansidar 2+ doses during pregnancy
|
53.7
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
554 |
484125
|
SP/Fansidar 3+ doses during pregnancy
|
15.4
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
555 |
484137
|
SP/Fansidar use during antenatal visit
|
75.5
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
556 |
484138
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
52.2
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
557 |
484139
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
15
|
1
|
SN
|
Senegal
|
2008
|
SN2008MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008-09
|
MIS
|
5406
|
5883
|
|
|
|
558 |
200693
|
SP/Fansidar use during pregnancy
|
68.1
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
559 |
200694
|
SP/Fansidar 2+ doses during pregnancy
|
40
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
560 |
200698
|
SP/Fansidar 3+ doses during pregnancy
|
13.2
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
561 |
200695
|
SP/Fansidar use during antenatal visit
|
64.9
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
562 |
200696
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
38.6
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
563 |
200697
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
12.7
|
1
|
SN
|
Senegal
|
2010
|
SN2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010-11
|
DHS
|
4516
|
4913
|
|
|
|
564 |
102827
|
SP/Fansidar use during pregnancy
|
75.5
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
565 |
102828
|
SP/Fansidar 2+ doses during pregnancy
|
42.2
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
566 |
102831
|
SP/Fansidar 3+ doses during pregnancy
|
4.6
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
567 |
102829
|
SP/Fansidar use during antenatal visit
|
73.5
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
568 |
102830
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
41.3
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
569 |
102832
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
4.5
|
1
|
SN
|
Senegal
|
2012
|
SN2012DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2012-13
|
DHS
|
2509
|
2710
|
|
|
|
570 |
138676
|
SP/Fansidar use during pregnancy
|
78.9
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
571 |
138677
|
SP/Fansidar 2+ doses during pregnancy
|
43.4
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
572 |
138680
|
SP/Fansidar 3+ doses during pregnancy
|
2.8
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
573 |
138678
|
SP/Fansidar use during antenatal visit
|
71.1
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
574 |
138679
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
40
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
575 |
138681
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
2.5
|
1
|
SN
|
Senegal
|
2014
|
SN2014DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014
|
DHS
|
2342
|
2584
|
|
|
|
576 |
114845
|
SP/Fansidar use during pregnancy
|
77.4
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
577 |
114846
|
SP/Fansidar 2+ doses during pregnancy
|
52.7
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
578 |
114850
|
SP/Fansidar 3+ doses during pregnancy
|
11.2
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
579 |
114847
|
SP/Fansidar use during antenatal visit
|
71.7
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
580 |
114848
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
49.4
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
581 |
114849
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
10.6
|
1
|
SN
|
Senegal
|
2015
|
SN2015DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015
|
DHS
|
2414
|
2712
|
|
|
|
582 |
245781
|
SP/Fansidar use during pregnancy
|
91.6
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
583 |
245782
|
SP/Fansidar 2+ doses during pregnancy
|
62.5
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
584 |
245777
|
SP/Fansidar 3+ doses during pregnancy
|
22.1
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
585 |
245783
|
SP/Fansidar use during antenatal visit
|
87.5
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
586 |
245784
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
60.3
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
587 |
245785
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
21.5
|
1
|
SN
|
Senegal
|
2016
|
SN2016DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
DHS
|
2316
|
2641
|
|
|
|
588 |
638844
|
SP/Fansidar use during pregnancy
|
94.3
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
589 |
638845
|
SP/Fansidar 2+ doses during pregnancy
|
62.6
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
590 |
638843
|
SP/Fansidar 3+ doses during pregnancy
|
22
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
591 |
638846
|
SP/Fansidar use during antenatal visit
|
92.2
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
592 |
638847
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
61.3
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
593 |
638848
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
21.6
|
1
|
SN
|
Senegal
|
2017
|
SN2017DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017
|
DHS
|
4447
|
4818
|
|
|
|
594 |
528497
|
SP/Fansidar use during pregnancy
|
93.1
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
595 |
528498
|
SP/Fansidar 2+ doses during pregnancy
|
64.4
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
596 |
528506
|
SP/Fansidar 3+ doses during pregnancy
|
22.4
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
597 |
528503
|
SP/Fansidar use during antenatal visit
|
90.8
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
598 |
528504
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
62.7
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
599 |
528505
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
21.6
|
1
|
SN
|
Senegal
|
2018
|
SN2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
2435
|
2681
|
|
|
|
600 |
3557
|
SP/Fansidar use during pregnancy
|
92.5
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
601 |
3558
|
SP/Fansidar 2+ doses during pregnancy
|
62.9
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
602 |
3556
|
SP/Fansidar 3+ doses during pregnancy
|
19.6
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
603 |
3565
|
SP/Fansidar use during antenatal visit
|
88.4
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
604 |
3566
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
59.9
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
605 |
3567
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
18.7
|
1
|
SN
|
Senegal
|
2019
|
SN2019DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2019
|
DHS
|
2327
|
2465
|
|
|
|
606 |
337925
|
SP/Fansidar use during pregnancy
|
92.3
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
607 |
337926
|
SP/Fansidar 2+ doses during pregnancy
|
67.4
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
608 |
337935
|
SP/Fansidar 3+ doses during pregnancy
|
37.7
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
609 |
337927
|
SP/Fansidar use during antenatal visit
|
86.1
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
610 |
337928
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
64.4
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
611 |
337929
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
36
|
1
|
SN
|
Senegal
|
2020
|
SN2020MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2020-21
|
MIS
|
2356
|
2637
|
|
|
|
612 |
51299
|
SP/Fansidar use during pregnancy
|
88.1
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
613 |
51300
|
SP/Fansidar 2+ doses during pregnancy
|
61.6
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
614 |
51304
|
SP/Fansidar 3+ doses during pregnancy
|
5
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
615 |
51301
|
SP/Fansidar use during antenatal visit
|
85
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
616 |
51302
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
59.8
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
617 |
51303
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
4.9
|
1
|
ST
|
Sao Tome and Principe
|
2008
|
ST2008DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2008-09
|
DHS
|
733
|
778
|
|
|
|
618 |
710368
|
SP/Fansidar use during pregnancy
|
1.5
|
1
|
SZ
|
Eswatini
|
2006
|
SZ2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006-07
|
DHS
|
1147
|
1152
|
|
|
|
619 |
710369
|
SP/Fansidar 2+ doses during pregnancy
|
0.5
|
1
|
SZ
|
Eswatini
|
2006
|
SZ2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006-07
|
DHS
|
1147
|
1152
|
|
|
|
620 |
710370
|
SP/Fansidar 3+ doses during pregnancy
|
0.5
|
1
|
SZ
|
Eswatini
|
2006
|
SZ2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006-07
|
DHS
|
1147
|
1152
|
|
|
|
621 |
3886
|
SP/Fansidar use during pregnancy
|
0.3
|
1
|
TD
|
Chad
|
2004
|
TD2004DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2004
|
DHS
|
2251
|
2116
|
|
|
|
622 |
54437
|
SP/Fansidar use during pregnancy
|
24.2
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
623 |
54443
|
SP/Fansidar 2+ doses during pregnancy
|
18.1
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
624 |
54445
|
SP/Fansidar 3+ doses during pregnancy
|
8.5
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
625 |
54444
|
SP/Fansidar use during antenatal visit
|
21.7
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
626 |
54446
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
16.4
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
627 |
54447
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
7.6
|
1
|
TD
|
Chad
|
2014
|
TD2014DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014-15
|
DHS
|
6742
|
6590
|
|
|
|
628 |
663763
|
SP/Fansidar use during pregnancy
|
76.8
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
629 |
663764
|
SP/Fansidar 2+ doses during pregnancy
|
56.7
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
630 |
663752
|
SP/Fansidar 3+ doses during pregnancy
|
22.8
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
631 |
663765
|
SP/Fansidar use during antenatal visit
|
58.7
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
632 |
663766
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
43.6
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
633 |
663767
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
19
|
1
|
TG
|
Togo
|
2013
|
TG2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013-14
|
DHS
|
2682
|
2782
|
|
|
|
634 |
774155
|
SP/Fansidar use during pregnancy
|
87.9
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
635 |
774157
|
SP/Fansidar 2+ doses during pregnancy
|
68.2
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
636 |
774161
|
SP/Fansidar 3+ doses during pregnancy
|
41.7
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
637 |
774158
|
SP/Fansidar use during antenatal visit
|
86.8
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
638 |
774159
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
67.6
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
639 |
774160
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
41.2
|
1
|
TG
|
Togo
|
2017
|
TG2017MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017
|
MIS
|
1315
|
1405
|
|
|
|
640 |
175836
|
SP/Fansidar use during pregnancy
|
53.3
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
641 |
175837
|
SP/Fansidar 2+ doses during pregnancy
|
22.3
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
642 |
175835
|
SP/Fansidar 3+ doses during pregnancy
|
2.8
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
643 |
175838
|
SP/Fansidar use during antenatal visit
|
49.5
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
644 |
175839
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
20.6
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
645 |
175840
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
2.7
|
1
|
TZ
|
Tanzania
|
2004
|
TZ2004DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2004-05
|
DHS
|
3500
|
3390
|
|
|
|
646 |
89648
|
SP/Fansidar use during pregnancy
|
58.9
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
647 |
89649
|
SP/Fansidar 2+ doses during pregnancy
|
30.7
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
648 |
89647
|
SP/Fansidar 3+ doses during pregnancy
|
7
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
649 |
89650
|
SP/Fansidar use during antenatal visit
|
57.4
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
650 |
89651
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
30.1
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
651 |
89652
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
6.8
|
1
|
TZ
|
Tanzania
|
2007
|
TZ2007AIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2007-08
|
AIS
|
3046
|
2968
|
|
|
|
652 |
192719
|
SP/Fansidar use during pregnancy
|
63.3
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
653 |
192720
|
SP/Fansidar 2+ doses during pregnancy
|
27.2
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
654 |
192718
|
SP/Fansidar 3+ doses during pregnancy
|
2.7
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
655 |
192721
|
SP/Fansidar use during antenatal visit
|
60.5
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
656 |
192722
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
26.3
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
657 |
192723
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
2.6
|
1
|
TZ
|
Tanzania
|
2010
|
TZ2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010
|
DHS
|
3266
|
3173
|
|
|
|
658 |
248730
|
SP/Fansidar use during pregnancy
|
62.6
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
659 |
248731
|
SP/Fansidar 2+ doses during pregnancy
|
33.2
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
660 |
248743
|
SP/Fansidar 3+ doses during pregnancy
|
4
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
661 |
248732
|
SP/Fansidar use during antenatal visit
|
59.6
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
662 |
248733
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
31.8
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
663 |
248741
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.9
|
1
|
TZ
|
Tanzania
|
2012
|
TZ2012AIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011-12
|
AIS
|
3555
|
3525
|
|
|
|
664 |
249212
|
SP/Fansidar use during pregnancy
|
69.4
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
665 |
249213
|
SP/Fansidar 2+ doses during pregnancy
|
35.3
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
666 |
249210
|
SP/Fansidar 3+ doses during pregnancy
|
8
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
667 |
249223
|
SP/Fansidar use during antenatal visit
|
68.3
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
668 |
249224
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
34.6
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
669 |
249225
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
7.7
|
1
|
TZ
|
Tanzania
|
2015
|
TZ2015DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2015-16
|
DHS
|
4167
|
4219
|
|
|
|
670 |
73655
|
SP/Fansidar use during pregnancy
|
83.1
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
671 |
73656
|
SP/Fansidar 2+ doses during pregnancy
|
56.1
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
672 |
73660
|
SP/Fansidar 3+ doses during pregnancy
|
25.8
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
673 |
73657
|
SP/Fansidar use during antenatal visit
|
81.4
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
674 |
73658
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
55.4
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
675 |
73659
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
25.5
|
1
|
TZ
|
Tanzania
|
2017
|
TZ2017MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2017
|
MIS
|
2947
|
3068
|
|
|
|
676 |
399848
|
SP/Fansidar use during pregnancy
|
79.2
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
677 |
399852
|
SP/Fansidar 2+ doses during pregnancy
|
58.4
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
678 |
399851
|
SP/Fansidar 3+ doses during pregnancy
|
31.7
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
679 |
399854
|
SP/Fansidar use during antenatal visit
|
74.6
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
680 |
399855
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
55.2
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
681 |
399856
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
30
|
1
|
TZ
|
Tanzania
|
2022
|
TZ2022DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2022
|
DHS
|
4335
|
4308
|
|
|
|
682 |
646461
|
SP/Fansidar use during pregnancy
|
36.6
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
683 |
646462
|
SP/Fansidar 2+ doses during pregnancy
|
17.6
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
684 |
646466
|
SP/Fansidar 3+ doses during pregnancy
|
6.1
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
685 |
646463
|
SP/Fansidar use during antenatal visit
|
33.5
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
686 |
646464
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
16.2
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
687 |
646465
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
5.7
|
1
|
UG
|
Uganda
|
2006
|
UG2006DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2006
|
DHS
|
3247
|
3239
|
|
|
|
688 |
137706
|
SP/Fansidar use during pregnancy
|
46.6
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
689 |
137707
|
SP/Fansidar 2+ doses during pregnancy
|
32.5
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
690 |
137708
|
SP/Fansidar 3+ doses during pregnancy
|
17
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
691 |
137720
|
SP/Fansidar use during antenatal visit
|
44.7
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
692 |
137721
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
31.7
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
693 |
137722
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
16.5
|
1
|
UG
|
Uganda
|
2009
|
UG2009MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2009
|
MIS
|
1464
|
1506
|
|
|
|
694 |
250634
|
SP/Fansidar use during pregnancy
|
48.4
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
695 |
250635
|
SP/Fansidar 2+ doses during pregnancy
|
26.7
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
696 |
250633
|
SP/Fansidar 3+ doses during pregnancy
|
10.3
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
697 |
250636
|
SP/Fansidar use during antenatal visit
|
44.9
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
698 |
250650
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
24.5
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
699 |
250651
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
9.4
|
1
|
UG
|
Uganda
|
2011
|
UG2011DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2011
|
DHS
|
3092
|
3019
|
|
|
|
700 |
108654
|
SP/Fansidar use during pregnancy
|
64.3
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
701 |
108655
|
SP/Fansidar 2+ doses during pregnancy
|
48.9
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
702 |
108652
|
SP/Fansidar 3+ doses during pregnancy
|
27.5
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
703 |
108656
|
SP/Fansidar use during antenatal visit
|
59.3
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
704 |
108651
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
45.2
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
705 |
108653
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
25.2
|
1
|
UG
|
Uganda
|
2014
|
UG2014MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2014-15
|
MIS
|
1820
|
1799
|
|
|
|
706 |
251431
|
SP/Fansidar use during pregnancy
|
78.5
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
707 |
251432
|
SP/Fansidar 2+ doses during pregnancy
|
45.9
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
708 |
251430
|
SP/Fansidar 3+ doses during pregnancy
|
17.2
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
709 |
251433
|
SP/Fansidar use during antenatal visit
|
76.9
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
710 |
251436
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
45
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
711 |
251437
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
16.8
|
1
|
UG
|
Uganda
|
2016
|
UG2016DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2016
|
DHS
|
5901
|
5992
|
|
|
|
712 |
593593
|
SP/Fansidar use during pregnancy
|
89
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
713 |
593594
|
SP/Fansidar 2+ doses during pregnancy
|
72.1
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
714 |
593626
|
SP/Fansidar 3+ doses during pregnancy
|
41
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
715 |
593595
|
SP/Fansidar use during antenatal visit
|
88.2
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
716 |
593596
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
71.7
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
717 |
593598
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
40.6
|
1
|
UG
|
Uganda
|
2018
|
UG2018MIS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018-19
|
MIS
|
2481
|
2635
|
|
|
|
718 |
723708
|
SP/Fansidar use during pregnancy
|
0.7
|
1
|
ZM
|
Zambia
|
2002
|
ZM2002DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2001-02
|
DHS
|
2667
|
2769
|
|
|
|
719 |
723709
|
SP/Fansidar use during antenatal visit
|
0.4
|
1
|
ZM
|
Zambia
|
2002
|
ZM2002DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2001-02
|
DHS
|
2667
|
2769
|
|
|
|
720 |
483134
|
SP/Fansidar use during pregnancy
|
86.8
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
721 |
483135
|
SP/Fansidar 2+ doses during pregnancy
|
65.7
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
722 |
483133
|
SP/Fansidar 3+ doses during pregnancy
|
43.1
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
723 |
483136
|
SP/Fansidar use during antenatal visit
|
82.4
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
724 |
483158
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
62.5
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
725 |
483159
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
40.9
|
1
|
ZM
|
Zambia
|
2007
|
ZM2007DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2007
|
DHS
|
2631
|
2615
|
|
|
|
726 |
252002
|
SP/Fansidar use during pregnancy
|
92.1
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
727 |
252003
|
SP/Fansidar 2+ doses during pregnancy
|
75.5
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
728 |
252030
|
SP/Fansidar 3+ doses during pregnancy
|
51.4
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
729 |
252004
|
SP/Fansidar use during antenatal visit
|
88.4
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
730 |
252005
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
72.7
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
731 |
252029
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
49.6
|
1
|
ZM
|
Zambia
|
2013
|
ZM2013DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2013-14
|
DHS
|
5074
|
5096
|
|
|
|
732 |
252063
|
SP/Fansidar use during pregnancy
|
94
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
733 |
252064
|
SP/Fansidar 2+ doses during pregnancy
|
81
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
734 |
252069
|
SP/Fansidar 3+ doses during pregnancy
|
58.7
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
735 |
252065
|
SP/Fansidar use during antenatal visit
|
93.7
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
736 |
252066
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
80.8
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
737 |
252067
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
58.6
|
1
|
ZM
|
Zambia
|
2018
|
ZM2018DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2018
|
DHS
|
3905
|
3958
|
|
|
|
738 |
673992
|
SP/Fansidar use during pregnancy
|
12.1
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
739 |
673993
|
SP/Fansidar 2+ doses during pregnancy
|
6.8
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
740 |
673996
|
SP/Fansidar 3+ doses during pregnancy
|
4.1
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
741 |
673994
|
SP/Fansidar use during antenatal visit
|
11.2
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
742 |
673995
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
6.3
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
743 |
673997
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
3.8
|
1
|
ZW
|
Zimbabwe
|
2005
|
ZW2005DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2005-06
|
DHS
|
2144
|
2132
|
|
|
|
744 |
483959
|
SP/Fansidar use during pregnancy
|
13.9
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_SPF
|
124903010
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPF
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
745 |
483960
|
SP/Fansidar 2+ doses during pregnancy
|
7.8
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_2SP
|
124903020
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SP
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
746 |
483918
|
SP/Fansidar 3+ doses during pregnancy
|
5
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_3SP
|
124903025
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SP
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
747 |
483961
|
SP/Fansidar use during antenatal visit
|
13.3
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_SPA
|
124903030
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPWSPA
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
748 |
483962
|
SP/Fansidar 2+ doses, at least one during ANC visit
|
7.3
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_2SA
|
124903040
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW2SA
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
749 |
483963
|
SP/Fansidar 3+ doses, at least one during ANC visit
|
4.8
|
1
|
ZW
|
Zimbabwe
|
2010
|
ZW2010DHS
|
ML_IPTP_W_3SA
|
124903050
|
I
|
1000
|
0
|
Total
|
Total
|
0
|
|
1
|
1
|
MLIPTPW3SA
|
|
2010-11
|
DHS
|
2448
|
2437
|
|
|
|
<<Previous
|
Next>>
|
|